Cargando…

Gut Microbiota and Coronary Artery Disease: Current Therapeutic Perspectives

The human gut microbiota is the community of microorganisms living in the human gut. This microbial ecosystem contains bacteria beneficial to their host and plays important roles in human physiology, participating in energy harvest from indigestible fiber, vitamin synthesis, and regulation of the im...

Descripción completa

Detalles Bibliográficos
Autores principales: Katsimichas, Themistoklis, Theofilis, Panagiotis, Tsioufis, Konstantinos, Tousoulis, Dimitris
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9963624/
https://www.ncbi.nlm.nih.gov/pubmed/36837875
http://dx.doi.org/10.3390/metabo13020256
_version_ 1784896298065854464
author Katsimichas, Themistoklis
Theofilis, Panagiotis
Tsioufis, Konstantinos
Tousoulis, Dimitris
author_facet Katsimichas, Themistoklis
Theofilis, Panagiotis
Tsioufis, Konstantinos
Tousoulis, Dimitris
author_sort Katsimichas, Themistoklis
collection PubMed
description The human gut microbiota is the community of microorganisms living in the human gut. This microbial ecosystem contains bacteria beneficial to their host and plays important roles in human physiology, participating in energy harvest from indigestible fiber, vitamin synthesis, and regulation of the immune system, among others. Accumulating evidence suggests a possible link between compositional and metabolic aberrations of the gut microbiota and coronary artery disease in humans. Manipulating the gut microbiota through targeted interventions is an emerging field of science, aiming at reducing the risk of disease. Among the interventions with the most promising results are probiotics, prebiotics, synbiotics, and trimethylamine N-oxide (TMAO) inhibitors. Contemporary studies of probiotics have shown an improvement of inflammation and endothelial cell function, paired with attenuated extracellular matrix remodeling and TMAO production. Lactobacilli, Bifidobacteria, and Bacteroides are some of the most well studied probiotics in experimental and clinical settings. Prebiotics may also decrease inflammation and lead to reductions in blood pressure, body weight, and hyperlipidemia. Synbiotics have been associated with an improvement in glucose homeostasis and lipid abnormalities. On the contrary, no evidence yet exists on the possible benefits of postbiotic use, while the use of antibiotics is not warranted, due to potentially deleterious effects. TMAO inhibitors such as 3,3-dimethyl-1-butanol, iodomethylcholine, and fluoromethylcholine, despite still being investigated experimentally, appear to possess anti-inflammatory, antioxidant, and anti-fibrotic properties. Finally, fecal transplantation carries conflicting evidence, mandating the need for further research. In the present review we summarize the links between the gut microbiota and coronary artery disease and elaborate on the varied therapeutic measures that are being explored in this context.
format Online
Article
Text
id pubmed-9963624
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99636242023-02-26 Gut Microbiota and Coronary Artery Disease: Current Therapeutic Perspectives Katsimichas, Themistoklis Theofilis, Panagiotis Tsioufis, Konstantinos Tousoulis, Dimitris Metabolites Review The human gut microbiota is the community of microorganisms living in the human gut. This microbial ecosystem contains bacteria beneficial to their host and plays important roles in human physiology, participating in energy harvest from indigestible fiber, vitamin synthesis, and regulation of the immune system, among others. Accumulating evidence suggests a possible link between compositional and metabolic aberrations of the gut microbiota and coronary artery disease in humans. Manipulating the gut microbiota through targeted interventions is an emerging field of science, aiming at reducing the risk of disease. Among the interventions with the most promising results are probiotics, prebiotics, synbiotics, and trimethylamine N-oxide (TMAO) inhibitors. Contemporary studies of probiotics have shown an improvement of inflammation and endothelial cell function, paired with attenuated extracellular matrix remodeling and TMAO production. Lactobacilli, Bifidobacteria, and Bacteroides are some of the most well studied probiotics in experimental and clinical settings. Prebiotics may also decrease inflammation and lead to reductions in blood pressure, body weight, and hyperlipidemia. Synbiotics have been associated with an improvement in glucose homeostasis and lipid abnormalities. On the contrary, no evidence yet exists on the possible benefits of postbiotic use, while the use of antibiotics is not warranted, due to potentially deleterious effects. TMAO inhibitors such as 3,3-dimethyl-1-butanol, iodomethylcholine, and fluoromethylcholine, despite still being investigated experimentally, appear to possess anti-inflammatory, antioxidant, and anti-fibrotic properties. Finally, fecal transplantation carries conflicting evidence, mandating the need for further research. In the present review we summarize the links between the gut microbiota and coronary artery disease and elaborate on the varied therapeutic measures that are being explored in this context. MDPI 2023-02-09 /pmc/articles/PMC9963624/ /pubmed/36837875 http://dx.doi.org/10.3390/metabo13020256 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Katsimichas, Themistoklis
Theofilis, Panagiotis
Tsioufis, Konstantinos
Tousoulis, Dimitris
Gut Microbiota and Coronary Artery Disease: Current Therapeutic Perspectives
title Gut Microbiota and Coronary Artery Disease: Current Therapeutic Perspectives
title_full Gut Microbiota and Coronary Artery Disease: Current Therapeutic Perspectives
title_fullStr Gut Microbiota and Coronary Artery Disease: Current Therapeutic Perspectives
title_full_unstemmed Gut Microbiota and Coronary Artery Disease: Current Therapeutic Perspectives
title_short Gut Microbiota and Coronary Artery Disease: Current Therapeutic Perspectives
title_sort gut microbiota and coronary artery disease: current therapeutic perspectives
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9963624/
https://www.ncbi.nlm.nih.gov/pubmed/36837875
http://dx.doi.org/10.3390/metabo13020256
work_keys_str_mv AT katsimichasthemistoklis gutmicrobiotaandcoronaryarterydiseasecurrenttherapeuticperspectives
AT theofilispanagiotis gutmicrobiotaandcoronaryarterydiseasecurrenttherapeuticperspectives
AT tsioufiskonstantinos gutmicrobiotaandcoronaryarterydiseasecurrenttherapeuticperspectives
AT tousoulisdimitris gutmicrobiotaandcoronaryarterydiseasecurrenttherapeuticperspectives